Equashield Reports Surge in Midyear Revenues, Global Expansion

Closed System Transfer Device Leader Increasingly Adopted by Global Market as Hazardous Drug Handling Safeguard

Aug 19, 2015, 08:00 ET from Equashield

PORT WASHINGTON, New York, August 19, 2015 /PRNewswire/ --

Equashield, a leading provider of Closed System Transfer Devices (CSTDs) for safe and simple handling of hazardous drugs, today announced a more than doubling of year-over-year revenue.  

Equashield reported a 106% increase in sales, with the upward financial growth capping off a twelve-month period of rapid expansion for the CSTD manufacturer.

Propelled by explosive penetration within the last 12 months into new global markets - throughout North America, Europe, Asia and Oceania - this momentum was marked by a 208% increase in sales to Equashield customers outside of the United States.

The technological innovations integrated in the EQUASHIELD® closed system - subsequently setting a new standard for safe, easy-to-use CSTDs - facilitated the establishment of new strategic partnerships with global distributors for the medical device producer.

"We are deeply appreciative that healthcare facilities throughout the world are increasingly choosing Equashield's Closed System Transfer Device over alternative products," said Marino Kriheli, Co-Founder of Equashield. "We are proud to offer a vital CSTD product to a market that is progressively recognizing the importance of providing an unparalleled level of protection to pharmacists and other healthcare professionals who work with hazardous medications. Introducing the second generation of EQUASHIELD® during a period of sharp sales growth resulted in supply challenges that needed to be successfully addressed. Equashield expanded production facilities and automated lines throughout the past year, which will allow for scalable future growth."

About Equashield  

Equashield is a leading provider of Closed System Transfer Devices (CSTDs), clinically proven to protect healthcare professionals from hazardous drug exposure. Incorporating a pioneering design, the company's flagship device, EQUASHIELD® II, covers more routes of exposure than alternative systems by preventing: contamination of syringe plungers, drug residuals on connector surfaces as well as exposure to drug vapor. No CSTD is faster to deploy or easier to use than EQUASHIELD®. The EQUASHIELD system has been cleared by the FDA under the ONB product code and substantiated in FDA-cleared labeling as preventing microbial ingress for up to seven days. 

For more information: www.equashield.com

Media Contact:
Finn Partners for Equashield
Nicole Grubner

SOURCE Equashield